fbpx

Ref. 23-2020 Postdoctoral Researcher to join its Hereditary Cancer Genetics Group

The Vall d´Hebron Institute of Oncology (VHIO) Seeks a “Postdoctoral Researcher to join its Hereditary Cancer Genetics Group”

 

Reference: Ref. 23-2020

Application deadline: 31/01/2021

Number of vacancies: 1

 

Job description:

VHIO’s Hereditary Cancer Genetics Group headed by Judith Balmaña MD PhD seeks a highly motivated postdoctoral lab-candidate interested in clinical cancer genetics. Our lab-research group focuses on two lines, which are genetic susceptibility to familial breast and ovarian cancer, and genetic risk to radiotherapy-induced side effects. We are especially committed to applying the potential clinical value of our findings to genetic diagnostic testing, interpretation of the effect of genetic variants, and radiogenomics.

More info about our group can be found at: https://www.vhio.net/en/hereditary-cancer-genetics

The successful candidate will be an integral part of the scientific team and will be involved in several research projects led by Sara Gutiérrez-Enríquez PhD, a senior investigator at Balmaña’s group. The appointed postdoc will be involved in the Dr Gutiérrez-Enríquez current work focused on: i) identifying microRNAs as biomarkers of normal tissue toxicity induced by radiotherapy using massively sequencing, ii) exploring the RNA-based genetic diagnostic using Nanopore long read sequencing and, iii) optimizing functional assays to test variant effects in patient-derived cells. The appointed individual will be also involved in the compilation of grant proposals, writing of manuscripts and supervising the work of graduate students.

 

Requirements:

An organized, motivated and team-oriented individual with prior experience working in massively sequencing with Illumina technology, RNA splicing functional assays, cell cultures, CRISPR-Cas9 edition and ideally with a background in cancer research.

We seek an individual with leadership skills, and capacity to plan, develop and execute research projects, with a genetic translational, patient-oriented vision of biomedical research. The candidate should have the amount of initiative needed to develop an evolving research plan according to the emergence of data and his/her personal research interests. He/she should be able to communicate well in English, even if it is not his/her first language. Bioinformatic skills and a previous postdoctoral stage will be favourably considered. Candidates must have at least one first-author publication in a prestigious journal.

 

Application:

To join our group please email a curriculum vitae, contact information of two references, and a cover letter describing past achievements and research interests to: Sara Gutiérrez-Enríquez sgutierrez@vhio.net.

Review of applications will commence immediately; interviews will be arranged with short-listed candidates. The candidate should be available to join the group ideally by February 2021, although there is some flexibility depending on the circumstances of the candidate, to be discussed during the interview.

 

About VHIO:

Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO), has established itself as a comprehensive cancer center of proven excellence internationally. It is also thanks to VHIO’s optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease.

Located within the Vall d’Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d’Hebron physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients.

VHIO’s pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread, and more effectively treating even the most undruggable tumor types.

 

VHIO’s translation toward precision oncology: http://www.vhio.net

 

Vall d’Hebron Institute Oncology (VHIO) endorses the Requirements and Principles of the European Charter for Researchers, the Code of Conduct for the Recruitment of Researchers promoted by the European Commission and follows Equal Opportunities policies.

On 10th April 2018 VHIO was awarded the “HR Excellence in Research” logo. Our Institute was consequently granted permission to use the HR Excellence in Research Award logo as demonstration of its stimulating and favourable work environment in line with the Charter & Code.

03/11/2020|